Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as GLPG1690 single ascending doses, GLPG1690 film-coated tablets, GLPG1690 film-coated, [14C]-GLPG1690 solution for infusion, GLPG1690 for infusion, [14C]-GLPG1690 capsules
GLPG1690 · 2 trials · 2 indications
The mRSS is a validated physical examination method for estimating skin thickness. The 17 body site mRSS was used, with each body site assessed on a scale of 0 (uninvolved) to 3 (severe thickening) with a total score range from 0 (best) to 51 (worst), with higher scores indicating greater severity of skin thickening.
The mRSS is a validated physical examination method for estimating skin thickness. The 17 body site mRSS was used, with each body site assessed on a scale of 0 (uninvolved) to 3 (severe thickening) with a total score range from 0 (best) to 51 (worst), with higher scores indicating greater severity of skin thickening.
The mRSS is a validated physical examination method for estimating skin thickness. The 17 body site mRSS was used, with each body site assessed on a scale of 0 (uninvolved) to 3 (severe thickening) with a total score range from 0 (best) to 51 (worst), with higher scores indicating greater severity of skin thickening.
The mRSS is a validated physical examination method for estimating skin thickness. The 17 body site mRSS was used, with each body site assessed on a scale of 0 (uninvolved) to 3 (severe thickening) with a total score range from 0 (best) to 51 (worst), with higher scores indicating greater severity of skin thickening.
LPA species C18:2 concentrations were determined in blood using a validated liquid chromatography tandem mass spectometry (LC/MS-MS) method. The baseline reference timepoint was Day -1 (mean of the pre-dosing duplicates).
LPA species C18:2 concentrations were determined in BALF using a validated LC/MS-MS method. The baseline reference timepoint was Day -1 (mean of the pre-dosing duplicates).
| Arm | Type | Description |
|---|---|---|
| GLPG1690 600 mg | EXPERIMENTAL | Participants received GLPG1690 600 milligrams (mg), orally once daily for 24 weeks. |
| Placebo | PLACEBO_COMPARATOR | Participants received GLPG1690 matching placebo, orally once daily for 24 weeks. |
| GLPG1690 600 mg once daily (QD) | EXPERIMENTAL | - |
| Placebo QD | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| GLPG1690 | DRUG | Film-coated tablets of GLPG1690 for oral use. |
| Placebo | DRUG | Film-coated tablets of GLPG1690 matching placebo for oral use. |
| GLPG1690 600 mg QD | DRUG | GLPG1690 capsules, administered at a dose of 600 mg, orally QD |
| Placebo QD | DRUG | Matching placebo capsules, administered orally QD |
Inclusion Criteria: * Able and willing to comply with the protocol requirements and to sign the informed consent form (ICF) as approved by the Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to any screening evaluations. * Male and female participants ≥18 years at the tim...
Top 15 of 17 competitors
GLPG1690 is an investigational small molecule being studied for the treatment of idiopathic pulmonary fibrosis and systemic sclerosis. It has been evaluated in Phase 2 clinical trials in both of these respiratory and fibrotic conditions. It is not approved for any indication.
GLPG1690 is being developed by Lakefront Biotherapeutics, which trades under the ticker LKFT. The company is the sponsor of the clinical program evaluating GLPG1690 in idiopathic pulmonary fibrosis and systemic sclerosis.
GLPG1690 is in Phase 2 clinical development. It has completed Phase 2 trials in idiopathic pulmonary fibrosis and systemic sclerosis. It is investigational and has not been approved by the FDA or any other regulatory agency.
GLPG1690 has been studied in two completed Phase 2 trials. NCT03798366 evaluated its effectiveness and safety in participants with systemic sclerosis across the United States, Belgium, Germany, Italy, Spain, and the United Kingdom. NCT02738801 assessed safety, tolerability, pharmacokinetics, and pharmacodynamics in subjects with idiopathic pulmonary fibrosis in Ukraine and the United Kingdom.
Yes, GLPG1690 film-coated tablets is one of several formulations and study labels used for the same investigational drug, GLPG1690. Other names include GLPG1690 oral suspension, GLPG1690 for infusion, [14C]-GLPG1690 solution for infusion, [14C]-GLPG1690 capsules, and GLPG1690 600 mg QD.